US2020246341A1PendingUtilityA1
Pharmaceutical composition for treating thyroid cancer comprising tyrosine kinase activity inhibitor as active ingredient
Assignee: KYUNGPOOK NATIONAL UNIV INDUSTRY-ACADEMIC COOPERATION FOUNDATIONPriority: Oct 20, 2017Filed: Oct 19, 2018Published: Aug 6, 2020
Est. expiryOct 20, 2037(~11.2 yrs left)· nominal 20-yr term from priority
A61P 35/04A61K 31/519
41
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A pharmaceutical composition containing a tyrosine kinase activity inhibitor as an active ingredient may increase the expression of sodium iodide symporter in thyroid cancer cells, thereby promoting iodine uptake and killing thyroid cancer cells. Thus, the composition may be useful for the treatment of thyroid cancer.
Claims
exact text as granted — not AI-modified1 . A composition for treating or preventing thyroid cancer containing, as an active ingredient, a compound of the following Formula 1, a salt thereof or a solvate thereof:
2 . The composition of claim 1 , wherein the thyroid cancer is anaplastic thyroid cancer or differentiated thyroid cancer.
3 . The composition of claim 1 , wherein the compound of Formula 1 increases expression of sodium iodide symporter.
4 . An anticancer adjuvant for thyroid cancer containing, as an active ingredient, a compound of the following Formula 1, a salt thereof or a solvate thereof:
5 . The anticancer adjuvant of claim 4 , wherein the compound of Formula 1 increases expression of sodium iodide symporter.Join the waitlist — get patent alerts
Track US2020246341A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.